"One Session Cures Everything" Claims

The claim

Headlines and personal stories sometimes say that a single psychedelic session cures depression, trauma, addiction or "everything". This page checks that claim against published trials. It is about clinical research on psilocybin and related treatments, not about anything people do outside a supervised study. Evidence labels: approved medicine, promising but limited, mixed, insufficient evidence and no good evidence of benefit.

What the best trials actually found

A US trial in major depression (psilocybin, 104 adults). Participants were randomized to a single dose of synthetic psilocybin or a niacin placebo, each given with psychological support. Psilocybin was associated with significantly reduced depression scores compared with niacin from baseline to day 43. [1] More participants receiving psilocybin had sustained response, but not remission, than those receiving niacin. [1] Psilocybin treatment was associated with a higher rate of overall adverse events and a higher rate of severe adverse events. [1] People with a history of psychosis or mania, active substance use disorder, or active suicidal ideation with intent were excluded. [1]

A large trial in treatment-resistant depression (233 adults). A single dose of a proprietary synthetic psilocybin formulation was compared with a control dose along with psychological support. Response and remission at three weeks supported the main result, but sustained response at 12 weeks did not. [2] Adverse events occurred in 179 of 233 participants (77%), and suicidal ideation or behavior or self-injury occurred in all dose groups. [2] The authors said larger and longer trials, including comparison with existing treatments, are required. [2] The study was funded by COMPASS Pathfinder. [2]

A comparison with an antidepressant. In a 6-month follow-up of 59 patients, both psilocybin therapy and the antidepressant escitalopram (with psychological support) produced sustained improvements, and the main difference between them was not statistically significant. [3] Safety in the follow-up period was not assessed. [3] In this trial, psilocybin therapy was two sessions plus extra support, not a single session.

People facing life-threatening illness. A Cochrane review of six randomized trials (149 participants) concluded that certainty of the evidence was low to very low. [4] The funding came from organizations that promote psychedelic-assisted therapy. [4]

Why "cure" is the wrong word

• Not every symptom is gone. In the US trial, sustained response did not mean remission. [1]
• Benefits can fade. Sustained response at 12 weeks was not supported in the larger trial. [2]
• It is not one dose alone. The trials combined the substance with preparation and psychological support. See What Is Psychedelic-Assisted Therapy?
• Harms exist. Suicidal thoughts or behavior occurred in all groups of one trial. [2]
• Harm tracking is uneven. A review of 214 studies found that of 68 studies published since 2005 only 16 described systematic approaches to adverse event assessment. [5] The same review found serious adverse events in about 4% of participants with preexisting neuropsychiatric disorders and none in healthy participants, and described classic psychedelics as generally well tolerated in clinical or research settings. [5]
• Expectations and blinding. Blinding is a recognized challenge in psychedelic trials, and the lack of effective blinding can introduce response bias. [6] Unblinding driven by expectations can influence effect sizes. [7]

Approval status

A "promising" trial is not an approval. NIDA says the FDA has granted Breakthrough Therapy designation for a few formulations of psilocybin being studied for depression. [8] NIDA describes the designation as given to support further research; it is not approval. [8] NIDA also states that only esketamine, a different substance, is FDA approved for therapeutic use among these drugs. [9] The FDA has also published final guidance for sponsors on designing clinical investigations of psychedelic drugs, which concerns research design and is not an approval. [10] See Medical Approval: What Is and Is Not Approved.

Testimonials are not evidence

A personal story can be honest and still not show cause. People who feel better may credit what they did last. Only controlled trials with comparison groups can separate the effect of a substance from time, support and expectation. Do not use any substance outside a regulated study on the strength of a story, and do not stop or change any medicine without your prescriber.

Evidence summary

See also Psychedelics for Major Depressive Disorder: Evidence Review and Psychedelic Clinical Trials and Research Limits. If you are in crisis, call or text 988 (US) or call 911.